Skip to main content
DNLI
NASDAQ Life Sciences

Denali Ends DNL151 Parkinson's Program After LUMA Trial Miss; Q4 AVLAYAH Guidance $30-32M

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$20.35
Mkt Cap
$3.217B
52W Low
$13.75
52W High
$27.3
52W Position info
48% above low
Off High info
25% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DNLI sits 48% above its 52-week low of $13.75.

Summary

Denali is scrapping DNL151 for idiopathic Parkinson's disease after the LUMA trial failed to hit its endpoints — the clearest negative in this recap and a write-off of a lead pipeline asset. Offsetting that, Q3 AVLAYAH revenue came in at $17.8 million, above guidance, and the company guided Q4 to $30-32 million, a step up in the launch. The balance sheet carries roughly $1.01 billion in cash and securities, so funding is not the near-term issue. Also in the mix: Takeda terminated the DNL593 agreement and rights reverted to Denali with development continuing, zafinofusp alfa is targeted for a 2027 BLA under accelerated approval, and the DNL952 Pompe Phase 1 study is enrolling with initial data expected in 2027. Morgan Stanley kept Overweight and lifted its target to $42 from $40. Watch the 2027 readout slate across five TransportVehicle programs and the zafinofusp alfa filing.

At the time of this announcement, DNLI was trading at $20.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $13.75 to $27.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

DNLI - Latest Insights

DNLI
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.45
Real-time Price: $19.70 info
Change: +$0.250 (+1%) info
Market Cap: $3.163B info
DNLI
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.45
Real-time Price: $19.70 info
Change: +$0.250 (+1%) info
Market Cap: $3.163B info
DNLI
Aug 06, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.10
Real-time Price: $19.70 info
Change: -$5.40 (-22%) info
Market Cap: $3.163B info
DNLI
Jun 18, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.89
Real-time Price: $19.70 info
Change: -$4.19 (-18%) info
Market Cap: $3.163B info
DNLI
Jun 18, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $23.89
Real-time Price: $19.70 info
Change: -$4.19 (-18%) info
Market Cap: $3.163B info